Heating up: heatwaves associated with increased ischaemic stroke risk
The burden of health issues caused by high temperatures is a major public health issue that is projected to increase …
The burden of health issues caused by high temperatures is a major public health issue that is projected to increase …
Pfizer’s prostate cancer therapy Talzenna, when combined with Xtandi, can extend overall survival (OS) by nearly nine months over the …
Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal growth factor …
Bristol Myers Squibb’s (BMJ) Phase III Relativity-098 trial examining its stage III-IV melanoma treatment, Opdualag, has failed to meet its …
Lindus Health is set to partner with the Clinical Data Interchange Standards Consortium (CDISC) to leverage AI in accelerating the …
By designing site-centric trials, sponsors can ensure their clinical trials also become patient-centric, said an expert at a conference. It is …
GlobalData estimates that by the end of 2024, there will be around 14.50 million diagnosed prevalent cases of men and …
TC BioPharm has completed subject dosing in Cohort A of the Phase IIb ACHIEVE trial of TCB008 in the UK, …
With 2025 well underway, the runaway momentum of artificial intelligence (AI) looks unstoppable. GlobalData estimates that the total AI market …
Johnson and Johnson (J&J) has announced the cancellation of its Phase III E.mbrace study examining Sanofi’s investigational vaccine for extraintestinal …
MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, for treating venous …
A once-weekly injection of semaglutide could cut alcohol cravings and reduce the amount someone living with alcohol use disorder (AUD) …
Selkirk Pharma has introduced a paradigm-shifting service, ClinFAST, for ensuring rapid small-volume clinical study materials delivery. The service is designed to …
Alto Neuroscience has reported positive outcomes from the interim analysis of its double-blind Phase IIb trial of oral ALTO-300, as …
AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ‘highest ever’ responses …